Orthofix Medical (NASDAQ:OFIX) Insider Aviva Mcpherron Sells 3,670 Shares of Stock

Orthofix Medical Inc. (NASDAQ:OFIX) insider Aviva Mcpherron sold 3,670 shares of the stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $9.38, for a total transaction of $34,424.60. Following the completion of the sale, the insider directly owned 66,330 shares of the company’s stock, valued at approximately $622,175.40. This trade represents a 5.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Orthofix Medical Stock Down 5.3%

Shares of OFIX opened at $8.95 on Tuesday. The business’s 50 day moving average is $11.05 and its 200 day moving average is $12.74. The company has a current ratio of 2.87, a quick ratio of 1.76 and a debt-to-equity ratio of 0.54. Orthofix Medical Inc. has a 12-month low of $8.88 and a 12-month high of $16.99. The company has a market capitalization of $361.76 million, a PE ratio of -5.93 and a beta of 0.72.

Orthofix Medical (NASDAQ:OFIX) last released its quarterly earnings data on Tuesday, May 5th. The medical device company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.16. Orthofix Medical had a negative net margin of 7.27% and a negative return on equity of 13.44%. The firm had revenue of $196.71 million for the quarter, compared to analysts’ expectations of $196.40 million. Research analysts expect that Orthofix Medical Inc. will post -1.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

OFIX has been the subject of several research analyst reports. Stifel Nicolaus decreased their price target on shares of Orthofix Medical from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, May 22nd. Wall Street Zen cut Orthofix Medical from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. TD Cowen reissued a “hold” rating on shares of Orthofix Medical in a research report on Thursday, May 21st. Canaccord Genuity Group cut their price target on Orthofix Medical from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, May 21st. Finally, Barrington Research decreased their price objective on Orthofix Medical from $17.00 to $15.00 and set an “outperform” rating for the company in a report on Friday, May 22nd. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $15.50.

Institutional Trading of Orthofix Medical

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Kestra Advisory Services LLC bought a new position in Orthofix Medical in the fourth quarter worth about $56,000. CWM LLC boosted its holdings in shares of Orthofix Medical by 136.4% in the 4th quarter. CWM LLC now owns 4,538 shares of the medical device company’s stock valued at $69,000 after buying an additional 2,618 shares in the last quarter. Abel Hall LLC bought a new stake in shares of Orthofix Medical in the 1st quarter valued at about $139,000. Mackenzie Financial Corp purchased a new position in shares of Orthofix Medical in the 3rd quarter worth approximately $148,000. Finally, Strs Ohio bought a new position in shares of Orthofix Medical during the 1st quarter worth approximately $150,000. Institutional investors own 89.76% of the company’s stock.

Orthofix Medical Company Profile

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.